<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35263489</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1930</StartPage><EndPage>1939</EndPage><MedlinePgn>1930-1939</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15321</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">This study was undertaken to determine the diagnostic and prognostic value of a panel of serum biomarkers and to correlate their concentrations with several clinical parameters in a large cohort of patients with amyotrophic lateral sclerosis (ALS).</AbstractText><AbstractText Label="METHODS">One hundred forty-three consecutive patients with ALS and a control cohort consisting of 70 patients with other neurodegenerative disorders (DEG), 70 patients with ALS mimic disorders (ALSmd), and 45&#xa0;healthy controls (HC) were included. Serum neurofilament light chain (NfL), ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1), glial fibrillary acidic protein (GFAP), and total tau protein levels were measured using ultrasensitive single molecule array.</AbstractText><AbstractText Label="RESULTS">NfL correlated with disease progression rate (p&#xa0;&lt;&#xa0;0.001) and with the measures of upper motor neuron burden (p&#xa0;&lt;&#xa0;0.001). NfL was higher in the ALS patients with classic and pyramidal phenotype. GFAP was raised in ALS with cognitive-behavioral impairment compared with ALS with normal cognition. NfL displayed the best diagnostic performance in discriminating ALS from HC (area under the curve [AUC]&#xa0;=&#xa0;0.990), DEG (AUC&#xa0;=&#xa0;0.946), and ALSmd (AUC&#xa0;=&#xa0;0.850). UCHL1 performed well in distinguishing ALS from HC (AUC&#xa0;=&#xa0;0.761), whereas it was not helpful in differentiating ALS from DEG and ALSmd. In multivariate analysis, NfL (p&#xa0;&lt;&#xa0;0.001) and UCHL1 (p&#xa0;=&#xa0;0.038) were independent prognostic factors. Survival analysis combining NfL and UCHL1 effectively stratified patients with lower NfL levels (p&#xa0;&lt;&#xa0;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">NfL is a useful biomarker for the diagnosis of ALS and the strongest predictor of survival. UCHL1 is an independent prognostic factor helpful in stratifying survival in patients with low NfL levels, likely to have slowly progressive disease. GFAP reflects extramotor involvement, namely cognitive impairment or frontotemporal dementia.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falzone</LastName><ForeName>Yuri Matteo</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domi</LastName><ForeName>Teuta</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelli</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Neuroimmunology Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schito</LastName><ForeName>Paride</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbieri</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazio</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volont&#xe8;</LastName><ForeName>Maria Antonietta</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnani</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Carro</LastName><ForeName>Ubaldo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Neurophysiology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrera</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unit of Genomics for Human Disease Diagnosis, Laboratory of Clinical Molecular Biology, Division of Genetics and Cell Biology, San Raffaele Hospital, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agosta</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neuroimaging Research Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quattrini</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furlan</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Neuroimmunology Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5485-0479</Identifier><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurophysiology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroimaging Research Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurorehabilitation Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Nilo</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0513-9517</Identifier><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurorehabilitation Unit, San Raffaele Scientific Institute, Scientific Institute for Research and Health Care, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Neurol. 2022 Jul;29(7):1867-1868</RefSource><PMID Version="1">35467797</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Neurol. 2023 Jan;30(1):283-284</RefSource><PMID Version="1">36176206</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Neurol. 2023 Jan;30(1):285-286</RefSource><PMID Version="1">36214082</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">UCHL1 protein</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">glial fibrillary acidic protein</Keyword><Keyword MajorTopicYN="N">neurofilament proteins</Keyword></KeywordList><CoiStatement>All the authors report no disclosures or conflicts of interest related to this article. M.F. is Editor&#x2010;in&#x2010;Chief of the <i>Journal of Neurology</i>, Associate Editor of <i>Human Brain Mapping</i>, Associate Editor of <i>Radiology</i>, and Associate Editor of <i>Neurological Sciences</i>; has received compensation for consulting services and/or speaking activities from Alexion, Almirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck&#x2010;Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck&#x2010;Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and Fondazione Italiana di Ricerca per la SLA (ARiSLA). F.A. is Associate Editor of <i>NeuroImage: Clinical</i>; has received compensation for consulting services and/or speaking activities from Novartis, Biogen Idec, Philips, and Roche; and receives or has received research support from the Italian Ministry of Health, AriSLA, and the European Research Council. None of the other authors has any conflict of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>9</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35263489</ArticleId><ArticleId IdType="pmc">PMC9314044</ArticleId><ArticleId IdType="doi">10.1111/ene.15321</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al&#x2010;Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primer. 2017;3(1):17071. doi:10.1038/nrdp.2017.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile F, Scarlino S, Falzone YM, et al. The peripheral nervous system in amyotrophic lateral sclerosis: opportunities for translational research. Front Neurosci. 2019;13:601. doi:10.3389/fnins.2019.00601</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00601</ArticleId><ArticleId IdType="pmc">PMC6603245</ArticleId><ArticleId IdType="pubmed">31293369</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Gentile F, Cerri F, et al. Phosphorylated TDP&#x2010;43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain. 2022;145(1):276&#x2010;284. doi:10.1093/brain/awab285</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab285</ArticleId><ArticleId IdType="pmc">PMC8967102</ArticleId><ArticleId IdType="pubmed">35076694</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2010;299. doi:10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population&#x2010;based study. Arch Neurol. 2000;57(1):109. doi:10.1001/archneur.57.1.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.1.109</ArticleId><ArticleId IdType="pubmed">10634456</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423&#x2010;433. doi:10.1016/S1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Chi&#xf2; A, Couratier P, et al. The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler. 2011;12(1):1&#x2010;10. doi:10.3109/17482968.2010.502940</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.502940</ArticleId><ArticleId IdType="pmc">PMC3513399</ArticleId><ArticleId IdType="pubmed">20698807</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone Y, Russo T, Domi T, et al. Current application of neurofilaments in amyotrophic lateral sclerosis and future perspectives. Neural Regen Res. 2021;16(10):1985. doi:10.4103/1673-5374.308072</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.308072</ArticleId><ArticleId IdType="pmc">PMC8343335</ArticleId><ArticleId IdType="pubmed">33642372</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Patin F, Descat A, et al. A pharmaco&#x2010;metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression. Guillemin GJ, Ed. PLoS One. 2018;13(6):e0198116. doi:10.1371/journal.pone.0198116</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0198116</ArticleId><ArticleId IdType="pmc">PMC5988280</ArticleId><ArticleId IdType="pubmed">29870556</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber NS, Shepheard SR, Sassani M, et al. Biomarkers in motor neuron disease: a state of the art review. Front Neurol. 2019;10:291. doi:10.3389/fneur.2019.00291</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00291</ArticleId><ArticleId IdType="pmc">PMC6456669</ArticleId><ArticleId IdType="pubmed">31001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157&#x2010;164. doi:10.1136/jnnp-2018-318704</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Preische O, Deuschle C, et al. Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry. 2016;87(11):1270&#x2010;1272. doi:10.1136/jnnp-2015-312972</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-312972</ArticleId><ArticleId IdType="pubmed">27188986</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. Reindl M, ed. PLoS One. 2013;8(9):e75091. doi:10.1371/journal.pone.0075091</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075091</ArticleId><ArticleId IdType="pmc">PMC3779219</ArticleId><ArticleId IdType="pubmed">24073237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald&#x2010;Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247&#x2010;2257. doi:10.1212/WNL.0000000000001642</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi D, Faravelli I, Meneri M, et al. Diagnostic and prognostic value of CSF neurofilaments in a cohort of patients with motor neuron disease: a cross&#x2010;sectional study. J Cell Mol Med. 2021;25(8):3765&#x2010;3771. doi:10.1111/jcmm.16240</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.16240</ArticleId><ArticleId IdType="pmc">PMC8051694</ArticleId><ArticleId IdType="pubmed">33609080</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90(1):e22&#x2010;e30. doi:10.1212/WNL.0000000000004761</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004761</ArticleId><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Goossens J, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2019;45(3):291&#x2010;304. doi:10.1111/nan.12511</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12511</ArticleId><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265(3):510&#x2010;521. doi:10.1007/s00415-017-8730-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8730-6</ArticleId><ArticleId IdType="pubmed">29322259</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodovitch A, Boucraut J, Delmont E, et al. Combination of serum and CSF neurofilament&#x2010;light and neuroinflammatory biomarkers to evaluate ALS. Sci Rep. 2021;11(1):703. doi:10.1038/s41598-020-80370-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80370-6</ArticleId><ArticleId IdType="pmc">PMC7803734</ArticleId><ArticleId IdType="pubmed">33436881</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88(24):2302&#x2010;2309. doi:10.1212/WNL.0000000000004029</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H. Biomarkers for Alzheimer&#x2019;s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643&#x2010;663. doi:10.1111/joim.12816</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12816</ArticleId><ArticleId IdType="pubmed">30051512</ArticleId></ArticleIdList></Reference><Reference><Citation>Day INM, Thompson RJ. UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Prog Neurogibol. 2010;90(3):327&#x2010;362. doi:10.1016/j.pneurobio.2009.10.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2009.10.020</ArticleId><ArticleId IdType="pubmed">19879917</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Povysheva N, Rose ME, et al. Role of UCHL1 in axonal injury and functional recovery after cerebral ischemia. Proc Natl Acad Sci. 2019;116(10):4643&#x2010;4650. doi:10.1073/pnas.1821282116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1821282116</ArticleId><ArticleId IdType="pmc">PMC6410860</ArticleId><ArticleId IdType="pubmed">30760601</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT. The UCH&#x2010;L1 gene encodes two opposing enzymatic activities that affect &#x3b1;&#x2010;synuclein degradation and Parkinson&#x2019;s disease susceptibility. Cell. 2002;111(2):209&#x2010;218. doi:10.1016/S0092-8674(02)01012-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(02)01012-7</ArticleId><ArticleId IdType="pubmed">12408865</ArticleId></ArticleIdList></Reference><Reference><Citation>Barschke P, Oeckl P, Steinacker P, et al. Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. J Neurol Neurosurg Psychiatry. 2020;91(5):503&#x2010;511. doi:10.1136/jnnp-2019-322476</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322476</ArticleId><ArticleId IdType="pubmed">32132225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, Wuolikainen A, Wu J, et al. Targeted multiple reaction monitoring analysis of CSF identifies UCHL1 and GPNMB as candidate biomarkers for ALS. J Mol Neurosci. 2019;69(4):643&#x2010;657. doi:10.1007/s12031-019-01411-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-019-01411-y</ArticleId><ArticleId IdType="pmc">PMC6858390</ArticleId><ArticleId IdType="pubmed">31721001</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Wang J, Xie W, Liu J, Wang C. UCHL1 from serum and CSF is a candidate biomarker for amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7(8):1420&#x2010;1428. doi:10.1002/acn3.51141</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51141</ArticleId><ArticleId IdType="pmc">PMC7448153</ArticleId><ArticleId IdType="pubmed">32729234</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller C, Foiani MS, Moore K, et al. Plasma glial fibrillary acidic protein is raised in progranulin&#x2010;associated frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91(3):263&#x2010;270. doi:10.1136/jnnp-2019-321954</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321954</ArticleId><ArticleId IdType="pubmed">31937580</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Steinacker P, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry. 2019;90(1):4&#x2010;10. doi:10.1136/jnnp-2018-318868</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318868</ArticleId><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium for Frontotemporal Lobar Degeneration German , Oeckl P, Halbgebauer S, et al. Glial fibrillary acidic protein in serum is increased in alzheimer&#x2019;s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67(2):481&#x2010;488. doi:10.3233/JAD-180325</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180325</ArticleId><ArticleId IdType="pubmed">30594925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiki A, Kamada M, Kawamura Y, et al. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer&#x2019;s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016;136(2):258&#x2010;261. doi:10.1111/jnc.13399</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13399</ArticleId><ArticleId IdType="pubmed">26485083</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Linker G, Mirza N, et al. Decreased &#x3b2;&#x2010;amyloid 1&#x2013;42 and increased tau levels in cerebrospinal fluid of patients with alzheimer disease. JAMA. 2003;289(16):2094&#x2010;2103. doi:10.1001/jama.289.16.2094</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.289.16.2094</ArticleId><ArticleId IdType="pubmed">12709467</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer&#x2019;s disease. Trends Neurosci. 1993;16(11):460&#x2010;465. doi:10.1016/0166-2236(93)90078-Z</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-2236(93)90078-Z</ArticleId><ArticleId IdType="pubmed">7507619</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66(6):852&#x2010;856. doi:10.1212/01.wnl.0000203120.85850.54</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000203120.85850.54</ArticleId><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, Elman L, McCluskey L, et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(4):442. doi:10.1001/jamaneurol.2013.6064</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6064</ArticleId><ArticleId IdType="pmc">PMC3989393</ArticleId><ArticleId IdType="pubmed">24492862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Deuschle C, Rattay TW, Maetzler W, Synofzik M. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36(2):1072&#x2010;1074. doi:10.1016/j.neurobiolaging.2014.10.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.10.019</ArticleId><ArticleId IdType="pubmed">25453560</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino P, Valentino F, Piccoli T, Piccoli F, La Bella V. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur J Neurol. 2009;16(2):257&#x2010;261. doi:10.1111/j.1468-1331.2008.02405.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2008.02405.x</ArticleId><ArticleId IdType="pubmed">19138331</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497&#x2010;503. doi:10.1016/j.clinph.2007.09.143</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011;70(1):79&#x2010;83. doi:10.1002/ana.22380</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22380</ArticleId><ArticleId IdType="pubmed">21437935</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Mora G, Sorar&#xf9; G, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double&#x2010;blind, randomised, placebo&#x2010;controlled, phase 2 trial. Lancet Neurol. 2019;18(2):155&#x2010;164. doi:10.1016/S1474-4422(18)30406-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30406-X</ArticleId><ArticleId IdType="pubmed">30554828</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G. PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740&#x2010;746. doi:10.1136/jnnp.2010.235952</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Ferraro PM, Riva N, et al. Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiol Aging. 2017;57:206&#x2010;219. doi:10.1016/j.neurobiolaging.2017.05.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.05.024</ArticleId><ArticleId IdType="pubmed">28666709</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis &#x2010; frontotemporal spectrum disorder (ALS&#x2010;FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Front Degener. 2017;18(3&#x2013;4):153&#x2010;174. doi:10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(9):2456&#x2010;2477. doi:10.1093/brain/awr179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Solca F, Carelli L, et al. The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Amyotroph Lateral Scler Front Degener. 2016;17(7&#x2013;8):489&#x2010;498. doi:10.1080/21678421.2016.1183679</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1183679</ArticleId><ArticleId IdType="pubmed">27219526</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzone YM, Domi T, Agosta F, et al. Serum phosphorylated neurofilament heavy&#x2010;chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. J Neurol. 2020;267(8):2272&#x2010;2280. doi:10.1007/s00415-020-09838-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09838-9</ArticleId><ArticleId IdType="pmc">PMC7166001</ArticleId><ArticleId IdType="pubmed">32306171</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95(1):e59&#x2010;e69. doi:10.1212/WNL.0000000000009559</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop P, Rocca D, Henley JM. Ubiquitin C&#x2010;terminal hydrolase L1 (UCH&#x2010;L1): structure, distribution and roles in brain function and dysfunction. Biochem J. 2016;473(16):2453&#x2010;2462. doi:10.1042/BCJ20160082</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160082</ArticleId><ArticleId IdType="pmc">PMC4980807</ArticleId><ArticleId IdType="pubmed">27515257</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Thal DR, Weishaupt JH, Ludolph AC, Otto M. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 2020;139(1):119&#x2010;134. doi:10.1007/s00401-019-02093-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02093-x</ArticleId><ArticleId IdType="pubmed">31701227</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion: Neurofilament Light in Presymptomatic ALS. Ann Neurol. 2018;84(1):130&#x2010;139. doi:10.1002/ana.25276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Dammer EB, Dai J, et al. A proteomic network approach across the als &#x2010; ftd disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med. 2018;10(1):48&#x2010;62. doi:10.15252/emmm.201708202</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201708202</ArticleId><ArticleId IdType="pmc">PMC5760858</ArticleId><ArticleId IdType="pubmed">29191947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Maestri E, et al. Serum C&#x2010;reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol. 2017;74(6):660. doi:10.1001/jamaneurol.2016.6179</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6179</ArticleId><ArticleId IdType="pmc">PMC5822215</ArticleId><ArticleId IdType="pubmed">28384752</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos D, Moreau C, Kyheng M, et al. A ferroptosis&#x2013;based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Sci Rep. 2019;9(1):2918. doi:10.1038/s41598-019-39739-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39739-5</ArticleId><ArticleId IdType="pmc">PMC6393674</ArticleId><ArticleId IdType="pubmed">30814647</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen I, Yacovzada NS, Yanowski E, et al. Circulating miR&#x2010;181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat Neurosci. 2021;24(11):1534&#x2010;1541. doi:10.1038/s41593-021-00936-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00936-z</ArticleId><ArticleId IdType="pubmed">34711961</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>